Serum Thrombopoietin and cMpl Expression in Thrombocytopenia of Different Etiologies

Hematology Reports - Italy
doi 10.4081/hr.2014.4996
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

PAGEPress Publications

Related search

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2015English

Thrombopoietin Receptor Agonists for the Treatment of Inherited Thrombocytopenia

Haematologica
Hematology
2020English

Switching Thrombopoietin Receptor Agonist Treatments in Patients With Primary Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2019English

Thrombopoietin Level Predicts Response to Treatment With Eltrombopag and Romiplostim in Immune Thrombocytopenia

American Journal of Hematology
Hematology
2018English

A United Kingdom Immune Thrombocytopenia (ITP) Forum Review of Practice: Thrombopoietin Receptor Agonists

British Journal of Haematology
Hematology
2016English

The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia

European Oncology and Haematology
OncologyHematology
2011English

Chorioretinal Folds Associated With Different Etiologies

Biomedical Journal of Scientific & Technical Research
2018English

Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia

British Journal of Haematology
Hematology
2018English

Deciphering Predictive Factors for Choice of Thrombopoietin Receptor Agonist, Treatment Free Responses, and Thrombotic Events in Immune Thrombocytopenia

Scientific Reports
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy